For decades, clinical research has largely operated through a site-centric model. Patients travelled to hospitals or specialist research centres for recruitment, assessments, monitoring, and follow-up, often requiring significant time, travel, and disruption to daily life. While this model established the foundation of modern clinical development, it also created barriers to participation, diversity, and retention.

Today, however, clinical research is undergoing a profound transformation. Driven by advances in digital technology, evolving patient expectations, and lessons learned during the COVID-19 pandemic, the industry is increasingly shifting toward a more patient-centric approach – one that prioritises accessibility, convenience, engagement, and real-world integration.

This evolution is not simply operational. It represents a broader cultural change in how clinical trials are designed, delivered, and experienced.

The Rise of the Patient-Centric Trial

Patient-centric clinical research aims to reduce the burden placed on participants while improving access to trials across wider populations. Rather than requiring patients to fit around the trial, the trial increasingly adapts around the patient.

This shift has accelerated the adoption of:

  • Telemedicine consultations
  • Home health visits
  • Remote patient monitoring
  • Wearable technologies
  • Electronic consent platforms
  • Direct-to-patient drug delivery
  • Hybrid and decentralised trial models

Collectively, these approaches are reshaping the traditional boundaries of clinical research and redefining what participation looks like.

Decentralised Clinical Trials: From Exception to Expectation

Decentralised clinical trials (DCTs) were once considered innovative alternatives suited only to specific studies or emergency circumstances. Today, they are becoming an increasingly established component of mainstream clinical development.

The pandemic demonstrated that many aspects of clinical research could continue remotely without compromising data integrity or patient safety. Sponsors, regulators, and investigators rapidly adopted digital infrastructure to maintain continuity of care and trial operations.

As a result, many organisations discovered unexpected benefits:

  • Improved patient recruitment
  • Greater geographic reach
  • Increased participant retention
  • Reduced travel burden
  • More representative patient populations
  • Enhanced real-world data capture

For patients living in rural areas, those with mobility challenges, or individuals balancing work and caregiving responsibilities, remote participation models may significantly improve access to clinical research opportunities.

Telemedicine and Virtual Engagement

Telemedicine has become one of the most visible components of patient-centric research. Virtual consultations allow investigators to conduct follow-up assessments, review adverse events, and maintain patient engagement without requiring frequent site visits.

This convenience can improve adherence and retention while reducing logistical complexity for participants. It also supports more continuous communication between patients and study teams, potentially improving the overall trial experience.

However, virtual engagement also raises important considerations around:

  • Data privacy and cybersecurity
  • Digital literacy
  • Technology accessibility
  • Cross-border regulatory compliance
  • Standardisation of remote assessments

As telemedicine becomes more integrated into clinical research, sponsors and regulators must ensure that digital convenience does not inadvertently create new forms of inequality or exclusion.

Home Health and Direct-to-Patient Models

Home health visits are also transforming the research landscape. Nurses and healthcare professionals can now perform many study procedures within a patient’s home environment, including blood draws, vital sign assessments, and drug administration.

Similarly, direct-to-patient (DTP) models allow investigational products to be delivered securely to participants, reducing the need for repeated site attendance.

These approaches can significantly reduce patient burden while supporting continuity and flexibility within long-term studies. At the same time, they introduce new operational and regulatory complexities involving:

  • Supply chain management
  • Cold-chain logistics
  • Drug accountability
  • Safety monitoring
  • Cross-jurisdictional regulations

As trials become more geographically distributed, robust oversight frameworks become increasingly important.

The Role of Digital Health Technologies

Wearables, mobile applications, and connected devices are now enabling continuous patient monitoring outside traditional clinical settings. This creates opportunities for richer, real-world datasets that may better reflect how patients experience disease and treatment in everyday life.

Digital biomarkers and remote monitoring tools may also allow earlier detection of adverse events, improved adherence tracking, and more personalised approaches to care.

Importantly, these technologies are contributing to a wider industry shift toward real-world evidence generation and longitudinal patient engagement beyond the confines of the trial site itself.

Regulatory Evolution

Regulatory agencies globally are increasingly adapting to support more flexible trial models. Organisations such as the U.S. Food and Drug Administration, European Medicines Agency, and Medicines and Healthcare products Regulatory Agency have all issued guidance surrounding decentralised trials, digital health technologies, and remote data collection.

Within the UK, the NHS is playing a key role in enabling this transition, with research increasingly embedded into routine care pathways to improve accessibility and participation in clinical trials.

However, patient-centric research also raises important regulatory questions around:

  • Validation of digital endpoints
  • Data quality and integrity
  • Informed consent processes
  • Patient privacy
  • Cross-border compliance
  • Oversight of remote trial activities

Balancing innovation with patient safety and scientific robustness remains a central challenge.

A More Human Model of Research?

At its core, the move toward patient-centric research reflects a growing recognition that clinical trials should be designed not only around scientific objectives, but around the realities of patients’ lives.

This does not mean traditional research sites will disappear. Instead, the future of clinical research is likely to involve hybrid ecosystems that combine physical sites, digital platforms, remote monitoring, and home-based care into more flexible and personalised models.

The long-term success of these approaches will depend not only on technology, but on trust, accessibility, regulatory alignment, and thoughtful implementation.

Clinical research is no longer solely about bringing patients to the trial site. Increasingly, it is about bringing research to the patient.

 

Back to News + Insights